Onconova Therapeutics Stock Z Score
ONTXDelisted Stock | USD 1.02 0.04 3.77% |
Onconova |
Onconova Therapeutics Company Z Score Analysis
Onconova Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Onconova Therapeutics Z Score | -32.73 |
Most of Onconova Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconova Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, Onconova Therapeutics has a Z Score of -32.73. This is 584.89% lower than that of the Pharmaceuticals sector and notably lower than that of the Health Care industry. The z score for all United States stocks is notably higher than that of the company.
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
All Next | Launch Module |
Onconova Fundamentals
Return On Equity | -0.84 | |||
Return On Asset | -0.38 | |||
Operating Margin | (89.28) % | |||
Current Valuation | (4.56 M) | |||
Shares Outstanding | 21 M | |||
Shares Owned By Insiders | 0.77 % | |||
Shares Owned By Institutions | 7.95 % | |||
Number Of Shares Shorted | 20.7 K | |||
Price To Earning | (0.87) X | |||
Price To Book | 1.43 X | |||
Price To Sales | 92.50 X | |||
Revenue | 226 B | |||
Gross Profit | 226 K | |||
EBITDA | (20.3 T) | |||
Net Income | (18.95 T) | |||
Cash And Equivalents | 46.53 M | |||
Cash Per Share | 2.23 X | |||
Debt To Equity | 1.26 % | |||
Current Ratio | 7.43 X | |||
Book Value Per Share | 0.69 X | |||
Cash Flow From Operations | (17.93 T) | |||
Short Ratio | 0.19 X | |||
Earnings Per Share | (0.96) X | |||
Target Price | 8.33 | |||
Number Of Employees | 16 | |||
Beta | 1.35 | |||
Market Capitalization | 20.9 M | |||
Total Asset | 22.68 T | |||
Retained Earnings | (482.63 T) | |||
Working Capital | 31.3 M | |||
Current Asset | 23.18 M | |||
Current Liabilities | 7.61 M | |||
Z Score | -32.73 | |||
Net Asset | 22.68 T |
About Onconova Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onconova Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onconova Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onconova Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |